PHARMO Institute for Drug Outcomes Research, Utrecht; Department of Obstetrics and Gynaecology, Erasmus MC, Rotterdam.
PHARMO Institute for Drug Outcomes Research, Utrecht.
Br J Gen Pract. 2023 Jun 29;73(732):e493-e501. doi: 10.3399/BJGP.2022.0193. Print 2023 Jul.
GPs have been shown to be important providers of medical care during pregnancy, however, little evidence exists on their awareness of pregnancy when prescribing medication to women.
To assess GPs' awareness of pregnancy and its association with prescribing medication with potential safety risks.
Population-based study using confirmed pregnancy records linked to GP records from the PHARMO Perinatal Research Network.
GPs' awareness of pregnancy, defined as the presence of a pregnancy confirmation in the GP information system during pregnancy, was assessed from 2004 to 2020. GP prescriptions of medication with potential safety risks were selected during pregnancy and its association with GPs' awareness of pregnancy was assessed using multivariable logistic regression.
A pregnancy confirmation was present in the GP records for 48% ( = 67 496/140 976) of selected pregnancies, increasing from 28% ( = 34/121) in 2004 to 63% in 2020 ( = 5763/9124). During 3% ( = 4489/140 976) of all pregnancies, the GP prescribed highly hazardous medication with teratogenic effects that should have been (temporarily) avoided. Pregnancy was GP confirmed for only 13% ( = 585/4489) at the first occurrence of such a prescription. Comparative analyses showed that women without a pregnancy confirmation were 59% more likely to be prescribed this highly hazardous medication (odds ratio [OR] 1.59, 95% confidence interval [CI] = 1.49 to 1.70) compared with those with a confirmed pregnancy.
Results of this study indicate a potential issue with GP awareness about pregnancy status at the time medication with potential safety risks is prescribed. Although pregnancy registration by GPs improved over the years, inadequate use still seems to be made of the available information systems for appropriate drug surveillance.
全科医生在女性怀孕期间提供医疗服务方面发挥着重要作用,但关于他们在为女性开具有潜在安全风险的药物时对妊娠的认识,证据甚少。
评估全科医生对妊娠的认识及其与开具有潜在安全风险的药物的关联性。
使用 PHARMO 围产期研究网络的确认妊娠记录与全科医生记录进行的基于人群的研究。
从 2004 年至 2020 年,评估全科医生对妊娠的认识,即妊娠期间全科医生信息系统中是否存在妊娠确认。选择妊娠期间有潜在安全风险的药物的全科医生处方,并使用多变量逻辑回归评估其与全科医生对妊娠认识的相关性。
在所选择的妊娠中,有 48%(=67496/140976)的妊娠记录中存在妊娠确认,从 2004 年的 28%(=34/121)增加到 2020 年的 63%(=5763/9124)。在所有妊娠中,有 3%(=4489/140976)的情况下,全科医生开具了有致畸作用的高度危险药物,这些药物本应(暂时)避免使用。在首次开具此类处方时,仅有 13%(=585/4489)的妊娠得到了全科医生的确认。比较分析表明,与有确认妊娠的女性相比,没有妊娠确认的女性开具这种高度危险药物的可能性高 59%(比值比 [OR] 1.59,95%置信区间 [CI] = 1.49 至 1.70)。
本研究结果表明,在开具有潜在安全风险的药物时,全科医生对妊娠状况的认识可能存在问题。尽管全科医生对妊娠的登记在过去几年中有所改善,但对现有信息系统的使用仍不够充分,无法进行适当的药物监测。